



CORRIGENDUM

Corrigendum to: Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster

Jun Liu^{1,#}, Jing Sun^{2,#}, Liping Luo^{1,#}, Yanhong Tang^{2,3,#}, Hu Guo^{2,#}, Yiyun He^{2,#}, Qi Liu¹, Xuya Yu⁴, Yumei Huang⁴, Siyuan Zhang⁵, Airu Zhu², Jun Dai^{6,*}, Fan Zhang^{4,*}, Tao Huang^{5,*}, Jincun Zhao^{2,7,8,9,10,*} and Yucai Peng^{1,*}

Corrigendum to: Jun Liu, Jing Sun, Liping Luo, Yanhong Tang, Hu Guo, Yiyun He, Qi Liu, Xuya Yu, Yumei Huang, Siyuan Zhang, Airu Zhu, Jun Dai, Fan Zhang, Tao Huang, Jincun Zhao, Yucai Peng. 2024. Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster. *Zoonoses*. Volume 4, Issue 18 (DOI: 10.15212/ZOONOSSES-2023-0060)

In the publication by Liu et al., the authors identified an error in Figure 1E. The middle column in Figure 1E was inadvertently missed during resubmission of the figure at the proofreading stage. The original submission contained the correct figure. The authors regret that this error was not identified during the final proof review.

The authors apologize for this error.

The correct version of Figure 1E is provided below.

#These authors contributed equally to this work.

*Corresponding authors

E-mail: 19915302@qq.com (JD); fan.zhang@aimbio.com (FZ); ymlc01@hncdc.com (TH); zhaojincun@gird.cn (JZ); pengyucai@live-rna.com (YP)

¹Liverna Therapeutics Inc., Zhuhai 519000, Guangdong, China

²State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, Guangdong, China

³Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Hunan Normal University, Changsha 410005, Hunan, China

⁴AIM Vaccine Co., Ltd., Beijing 100022, China

⁵Hunan Provincial Center for Disease Prevention and Control, Changsha 410153, Hunan, China

⁶Guangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China

⁷Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China

⁸Institute of Infectious disease, Guangzhou Eighth People's Hospital of Guangzhou Medical University, Guangzhou 510442, Guangdong, China

⁹Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou 510005, Guangdong, China

¹⁰Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong, China




FIGURE 1 | Design, characterization and immunogenicity evaluation of the mRNA vaccine against SARS-CoV-2. (A) Schematic diagram of the target antigen-Spike (S) protein, encoded by mRNA vaccines against the Wuhan-Hu-1. (B) The expression of S, S1 or RBD proteins in HEK293 cells transfected with *in vitro* transcribed mRNA was detected by western blot. (C) Animal experimental strategy. (D) The neutralizing titers against SARS-CoV-2 in animals were tested by FRNT. hACE2-KI mice, N=10. * $P < 0.05$, ** $P < 0.01$. (E) The viral loads of SARS-CoV-2 in animals were tested by qPCR. (F) H&E staining was used to examine histopathologic changes in the lung tissues. Scale bar, 600 μm (4x) or 200 μm (20x).